Mount Sinai wins $1 million prize for AI platform that speeds Alzheimer's research
Researchers at the Icahn School of Medicine at Mount Sinai have won the Alzheimer's Insights AI Prize for developing Biomni-AD, an AI system designed to compress months of data analysis into minutes. The award, announced March 20, was originally valued at $1 million but expanded to $2 million after the competition recognized two winning teams.
Dr. Kuan-lin Huang, an associate professor of genetics and genomic sciences at Mount Sinai, led the team. The project was developed in collaboration with Stanford University.
What Biomni-AD does
Biomni-AD functions as a "co-scientist" that integrates fragmented data from genomics, imaging, proteomics, and clinical studies into a single workflow. Researchers can ask complex questions in plain English and receive a complete analysis plan with code, figures, and reports.
The system handles tasks that typically require months of manual work in minutes. It connects genetics, single-cell data, CRISPR screens, biomarkers, and clinical datasets without requiring researchers to manually wrangle disparate sources.
Early testing has identified biological signals and prioritized drug targets faster than conventional methods, according to the researchers.
The problem it addresses
Alzheimer's disease affects roughly 50 million people worldwide today and is projected to affect more than 150 million by 2050. Massive datasets now exist across multiple research domains, but they remain fragmented and difficult to integrate.
This fragmentation creates a bottleneck. Researchers spend months preparing data for analysis rather than generating and testing hypotheses. Every month lost delays potential treatments reaching patients.
How it works
Biomni-AD is built as a partnership between human researchers and AI, not a replacement for either. Scientists review and approve the system's research plan before execution and can inspect each analytical step.
The platform includes more than 180 specialized tools and is built on a curated Alzheimer's data lake. It will be made freely available to researchers worldwide through the AD Data Initiative's AD Workbench platform.
Next steps
Mount Sinai plans to deploy Biomni-AD globally and launch collaborative "call-for-hypothesis" initiatives. The team will also establish an ADA Consortium to expand collaboration across institutions.
"No single lab is going to solve Alzheimer's alone," Huang said. "What we're building is a shared infrastructure-a way for thousands of researchers to work with a powerful AI as a partner, test more ideas, and reach answers faster."
Researchers interested in AI-powered approaches to scientific discovery may benefit from exploring AI Research Courses and AI Data Analysis Courses that cover multimodal data integration and advanced analytics workflows.
Your membership also unlocks:
